Christos S Karapetis

List of Publications by Year in Descending Order

83 papers	6,439 citations	22 h-index	80 g-index
90 ext. papers	7,272 ext. citations	6.2 avg, IF	5.1 L-index

#	Paper	IF	Citations
83	Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunotherapies.. *Journal of Thoracic Oncology*, **2022**,	8.9	3
82	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.. *BMC Cancer*, **2022**, 22, 222	4.8	0
81	Investigating the breast cancer screening-treatment-mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data. *European Journal of Cancer Care*, **2021**, 31, e13539	2.4	0
80	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. *British Journal of Cancer*, **2021**,	8.7	8
79	A collaborative approach to meeting oncology challenges in island communities in the Asia-Pacific region. *Journal of Medical Imaging and Radiation Oncology*, **2021**, 65, 418-423	1.7	1
78	Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. *Cancer Chemotherapy and Pharmacology*, **2021**, 88, 39-52	3.5	
77	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. *PLoS Medicine*, **2021**, 18, e1003620	11.6	16
76	Second-line FOLFOX chemotherapy for advanced biliary tract cancer. *Lancet Oncology, The*, **2021**, 22, e286	21.7	
75	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. *International Journal of Cancer*, **2021**, 148, 1014-1026	7.5	26
74	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. *Current Problems in Cancer*, **2021**, 45, 100637	2.3	6
73	Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. *Clinical Cancer Research*, **2021**, 27, 52-59	12.9	6
72	Australia and New Zealand's responsibilities in improving oncology services in the Asia-Pacific: A call to action. *Asia-Pacific Journal of Clinical Oncology*, **2021**,	1.9	2
71	Female breast cancer treatment and survival in South Australia: Results from linked health data. *European Journal of Cancer Care*, **2021**, 30, e13451	2.4	2
70	Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. *European Journal of Clinical Pharmacology*, **2021**, 1	2.8	0
69	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. *JCO Oncology Practice*, **2020**, 16, 467-482	2.3	37
68	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. *Expert Review of Anticancer Therapy*, **2020**, 20, 251-270	3.5	3
67	Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. *Clinical Cancer Research*, **2020**, 26, 3280-3286	12.9	18

66	Dose modification for haematological toxicity: a survey of Australian medical oncologists. *Internal Medicine Journal*, **2020**, 50, 1338-1343	1.6	0
65	Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. *European Urology*, **2020**, 78, 540-543	10.2	33
64	Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. *Clinical Cancer Research*, **2020**, 26, 5487-5493	12.9	23
63	Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. *Asia-Pacific Journal of Clinical Oncology*, **2020**, 16, e139-e145	1.9	6
62	Cardiotoxicity after cancer treatment: a process map of the patient treatment journey. *Cardio-Oncology*, **2019**, 5, 14	2.8	5
61	Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia. *BMC Cancer*, **2019**, 19, 856	4.8	4
60	Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, e208	8.9	1
59	Authors' Reply. *Journal of Thoracic Oncology*, **2019**, 14, e210	8.9	
58	Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. *Journal of Thoracic Oncology*, **2019**, 14, 1440-1446	8.9	53
57	Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry". *Targeted Oncology*, **2019**, 14, 367-368	5	
56	Internet use and preferences among women living with advanced breast cancer. *Breast Journal*, **2019**, 25, 290-295	1.2	3
55	Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. *Targeted Oncology*, **2019**, 14, 743-748	5	4
54	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. *Journal of Thoracic Disease*, **2019**, 11, 4241-4248	2.6	6
53	Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). *EBioMedicine*, **2019**, 50, 433-441	8.8	21
52	The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. *Frontiers in Genetics*, **2019**, 10, 1118	4.5	39
51	Outcomes of Older Patients (≥70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. *Clinical Colorectal Cancer*, **2019**, 18, e140-e149	3.8	4
50	Online information and support needs of women with advanced breast cancer: a qualitative analysis. *Supportive Care in Cancer*, **2018**, 26, 3489-3496	3.9	20
49	Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. *Asia-Pacific Journal of Clinical Oncology*, **2018**, 14, e64-e70	1.9	6

48	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases". *Annals of Surgery*, **2018**, 268, e9-e10	7.8	
47	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes for Patients With Indeterminate Extrahepatic Disease on 18FDG-PET Scan Before Liver Resection for Metastatic Colorectal Cancer. *Annals of Surgical Oncology*, **2018**, 25, 2731-2738	7.8	3
46	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. *Acta Oncologica*, **2018**, 57, 1438-1444	3.2	48
45	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. *Internal Medicine Journal*, **2018**, 48, 774-779	1.6	16
44	Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing. *Annals of Surgical Oncology*, **2018**, 25, 2731-2738	3.1	12
43	Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 1741-1750	4.9	21
42	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Wild-Type Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2018**, 24, 3838-3844	12.9	5
41	The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. *Frontiers in Oncology*, **2018**, 8, 275	5.3	19
40	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. *Clinical Colorectal Cancer*, **2018**, 17, 313-319	3.8	6
39	Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. *Journal of Evaluation in Clinical Practice*, **2018**, 24, 135-144	2.5	7
38	Acanthosis Palmaris: A Rare Paraneoplastic Manifestation of Non-Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2018**, 14, 331-332	3.1	
37	Author reply. *Internal Medicine Journal*, **2018**, 48, 1415-1416	1.6	
36	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. *Cancers*, **2018**, 10,	6.6	2
35	Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study. *Asia Pacific Journal of Clinical Nutrition*, **2018**, 27, 962-967	1	1
34	Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. *Internal Medicine Journal*, **2017**, 47, 408-414	1.6	4
33	Female breast cancer management and survival: The experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. *Journal of Evaluation in Clinical Practice*, **2017**, 23, 1433-1443	2.5	4
32	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. *Clinical Colorectal Cancer*, **2016**, 15, 32-6	3.8	27
31	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. *Annals of Surgical Oncology*, **2016**, 23, 3616-3622	3.1	11

30	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. *European Journal of Cancer*, **2016**, 55, 122-30	7.5	26
29	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2016**, 15, 95-103	3.8	22
28	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. *Expert Review of Anticancer Therapy*, **2016**, 16, 557-71	3.5	2
27	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. *Molecular Diagnosis and Therapy*, **2016**, 20, 75-82	4.5	5
26	Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	7
25	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. *Journal of Clinical Oncology*, **2016**, 34, 2258-64	2.2	41
24	Fc-□Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 2435-44	12.9	24
23	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. *Expert Review of Molecular Diagnostics*, **2015**, 15, 1033-48	3.8	
22	Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’. *British Journal of Cancer*, **2015**, 113, 1635	8.7	6
21	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. *PLoS ONE*, **2015**, 10, e0135599	3.7	19
20	Colorectal cancer: Metastases to a single organ. *World Journal of Gastroenterology*, **2015**, 21, 11767-76	5.6	147
19	Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. *Cancer Medicine*, **2015**, 4, 1461-71	4.8	12
18	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. *Clinical Cancer Research*, **2014**, 20, 744-53	12.9	117
17	Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. *Clinical Colorectal Cancer*, **2014**, 13, 87-93	3.8	43
16	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. *Medical Journal of Australia*, **2014**, 201, 462-6	4	6
15	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. *Expert Review of Anticancer Therapy*, **2014**, 14, 1477-93	3.5	12
14	Current opinion on optimal treatment for colorectal cancer. *Expert Review of Anticancer Therapy*, **2013**, 13, 597-611	3.5	24
13	A population-based study of metastatic colorectal cancer in individuals aged □80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. *Cancer*, **2013**, 119, 722-8	6.4	33

12	Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 820-7	5	26
11	Personalized treatment for advanced colorectal cancer: KRAS and beyond. *Cancer Management and Research*, **2013**, 5, 387-400	3.6	15
10	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. *European Journal of Cancer*, **2012**, 48, 1293-8	7.5	19
9	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. *Colorectal Cancer*, **2012**, 1, 137-148	0.8	1
8	A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. *Asia-Pacific Journal of Clinical Oncology*, **2010**, 6, 298-305	1.9	3
7	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. *JAMA - Journal of the American Medical Association*, **2010**, 304, 1812-20	27.4	580
6	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. *Clinical Colorectal Cancer*, **2010**, 9, 8-14	3.8	7
5	Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. *Journal of Clinical Oncology*, **2009**, 27, 1822-8	2.2	95
4	Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?. *Asia-Pacific Journal of Clinical Oncology*, **2009**, 5, 24-31	1.9	
3	Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. *Journal of the National Cancer Institute*, **2009**, 101, 1182-92	9.7	104
2	K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *New England Journal of Medicine*, **2008**, 359, 1757-65	59.2	2912
1	Cetuximab for the treatment of colorectal cancer. *New England Journal of Medicine*, **2007**, 357, 2040-8	59.2	1587